Free shipping on all orders over $ 500

Cantuzumab ravtansine

Cat. No. M25258
Cantuzumab ravtansine Structure
Synonym:

IMGN242; huC242-DM4

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?
Quality Control & Documentation
Biological Activity

Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody huC242 covalently linked via a disulfide bond to DM4. Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts.

Chemical Information
CAS Number 868747-45-9
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Jordi Rodon, et al. Cancer Chemother Pharmacol. Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study

[2] Suzanne V Smith. Curr Opin Mol Ther. Technology evaluation: cantuzumab mertansine, ImmunoGen

[3] Paul R Helft, et al. Clin Cancer Res. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors

[4] Hongsheng Xie, et al. J Pharmacol Exp Ther. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice

[5] Anthony W Tolcher, et al. J Clin Oncol. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

Related Drug-Linker Conjugates for ADC Products
SC-VC-PAB-MMAE

SC-VC-PAB-MMAE is part of a drug-linker conjugate for ADC (ADC) with anticancer activity, which consists of MMAE (a tubulin inhibitor) linked to a cleavable SC-VC-PAB linker.
DBCO-(PEG)3-VC-PAB-MMAE

DBCO-(PEG)3-vc-PAB-MMAE is an active molecule coupler (drug-linker conjugate for ADC) consisting of auristatin E attached to a DBCO-(PEG)3-vc-PAB connector. It can be used for cancer research. In addition, DBCO-(PEG)3-vc-PAB-MMAE is a click chemistry that contains a DBCO moiety and can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing an Azide moiety.
PB038

PB038 is a drug-liker containing a PEG unit and a cleavable linker attached to Exatecan.
Val-Ala-PAB-MMAE

Val-Ala-PAB-MMAE is a Drug-Linker Conjugate for ADC, consisting of ADC linker (Val-Ala-PAB) and MMAE.
Val-Ala-PABC-Exatecan

Val-Ala-PABC-Exatecan is a Drug-Linker Conjugates for ADC, consiting of a cleavable Tesirine linker (Val-Ala-PABC) and Exatecan (topoisomerase I inhibitor).
  Catalog
Abmole Inhibitor Catalog




Keywords: Cantuzumab ravtansine, IMGN242; huC242-DM4 supplier, Drug-Linker Conjugates for ADC, inhibitors, activators

 
Get to Know Us
Customer Support
Resources
Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.